{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:26Z","timestamp":1791924206531,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["CMRO11303"],"award-info":[{"award-number":["CMRO11303"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04147-4","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:29:19Z","timestamp":1759206559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk"],"prefix":"10.1007","volume":"74","author":[{"given":"Cheng-Wei","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Wen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsuan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Chih","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"4147_CR1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00345-018-2332-5","volume":"36","author":"M Rouanne","year":"2018","unstructured":"Rouanne M, Roumigui\u00e9 M, Hou\u00e9d\u00e9 N et al (2018) Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol 36:1727\u20131740. https:\/\/doi.org\/10.1007\/s00345-018-2332-5","journal-title":"World J Urol"},{"key":"4147_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131:58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033","journal-title":"Blood"},{"key":"4147_CR3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48:434\u2013452. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014","journal-title":"Immunity"},{"key":"4147_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86. https:\/\/doi.org\/10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"key":"4147_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"4147_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","volume":"14","author":"K Sury","year":"2018","unstructured":"Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14:571\u2013588. https:\/\/doi.org\/10.1038\/s41581-018-0035-1","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"4147_CR7","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","volume":"183","author":"MF Krummel","year":"1996","unstructured":"Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183(6):2533\u20132540. https:\/\/doi.org\/10.1084\/jem.183.6.2533","journal-title":"J Exp Med"},{"issue":"15_suppl","key":"4147_CR8","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/jco.2011.29.15_suppl.2505","volume":"29","author":"MK Callahan","year":"2011","unstructured":"Callahan MK, Yang AS, Tandon S et al (2011) Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol 29(15_suppl):2505","journal-title":"J Clin Oncol"},{"key":"4147_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6:38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"4147_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.34067\/kid.0000852019","volume":"1","author":"S Gupta","year":"2020","unstructured":"Gupta S, Cortazar FB, Riella LV, Leaf DE (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360 1:130\u2013140. https:\/\/doi.org\/10.34067\/kid.0000852019","journal-title":"Kidney360"},{"key":"4147_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638\u2013647. https:\/\/doi.org\/10.1016\/j.kint.2016.04.008","journal-title":"Kidney Int"},{"key":"4147_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/cji.0000000000000338","volume":"44","author":"JD Sorah","year":"2021","unstructured":"Sorah JD, Rose TL, Radhakrishna R, Derebail VK, Milowsky MI (2021) Incidence and prediction of immune checkpoint inhibitor-related nephrotoxicity. J Immunother 44:127\u2013131. https:\/\/doi.org\/10.1097\/cji.0000000000000338","journal-title":"J Immunother"},{"key":"4147_CR13","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/cjn.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF et al (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1692\u20131700. https:\/\/doi.org\/10.2215\/cjn.00990119","journal-title":"Clin J Am Soc Nephrol"},{"key":"4147_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ekir.2019.11.015","volume":"5","author":"S Manohar","year":"2020","unstructured":"Manohar S, Thongprayoon C, Cheungpasitporn W, Markovic SN, Herrmann SM (2020) Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients. Kidney Int Rep 5:149\u2013158. https:\/\/doi.org\/10.1016\/j.ekir.2019.11.015","journal-title":"Kidney Int Rep"},{"key":"4147_CR15","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"key":"4147_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","volume":"107","author":"SM Herrmann","year":"2025","unstructured":"Herrmann SM, Abudayyeh A, Gupta S et al (2025) Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int 107:21\u201332. https:\/\/doi.org\/10.1016\/j.kint.2024.09.017","journal-title":"Kidney Int"},{"key":"4147_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","author":"S Gupta","year":"2021","unstructured":"Gupta S, Short SAP, Sise ME et al (2021) Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003467","journal-title":"J Immunother Cancer"},{"key":"4147_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103434","volume":"165","author":"A Inno","year":"2021","unstructured":"Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S, Petrelli F (2021) Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 165:103434. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103434","journal-title":"Crit Rev Oncol Hematol"},{"key":"4147_CR19","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1111\/1759-7714.15063","volume":"14","author":"Y Feng","year":"2023","unstructured":"Feng Y, Tao Y, Chen H, Zhou Y, Tang L, Liu C, Hu X, Shi Y (2023) Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer 14:2536\u20132547. https:\/\/doi.org\/10.1111\/1759-7714.15063","journal-title":"Thorac Cancer"},{"key":"4147_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10:89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"4147_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.34067\/kid.0000152019","volume":"1","author":"S Manohar","year":"2020","unstructured":"Manohar S, Ghamrawi R, Chengappa M et al (2020) Acute interstitial nephritis and checkpoint inhibitor therapy: single center experience of management and drug rechallenge. Kidney360 1:16\u201324. https:\/\/doi.org\/10.34067\/kid.0000152019","journal-title":"Kidney360"},{"key":"4147_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","volume":"147","author":"M Espi","year":"2021","unstructured":"Espi M, Teuma C, Novel-Catin E, Maillet D, Souquet PJ, Dalle S, Koppe L, Fouque D (2021) Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. Eur J Cancer 147:29\u201339. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.005","journal-title":"Eur J Cancer"},{"key":"4147_CR23","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/ckj\/sfaa008","volume":"14","author":"D Oleas","year":"2021","unstructured":"Oleas D, Bolufer M, Agraz I et al (2021) Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J 14:1364\u20131370. https:\/\/doi.org\/10.1093\/ckj\/sfaa008","journal-title":"Clin Kidney J"},{"key":"4147_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252978","volume":"16","author":"MS Koks","year":"2021","unstructured":"Koks MS, Ocak G, Suelmann BBM, Hulsbergen-Veelken CAR, Haitjema S, Vianen ME, Verhaar MC, Kaasjager KAH, Khairoun M (2021) Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study. PLoS ONE 16:e0252978. https:\/\/doi.org\/10.1371\/journal.pone.0252978","journal-title":"PLoS ONE"},{"key":"4147_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/0284186x.2023.2176255","volume":"62","author":"A Valentin","year":"2023","unstructured":"Valentin A, M\u00f8ller AKH, Palshof JA, Broberg B, Gravesen E, Svane IM, Hansen D (2023) Combination therapy with immune check point inhibitors and acute kidney injury. Acta Oncol 62:121\u2013125. https:\/\/doi.org\/10.1080\/0284186x.2023.2176255","journal-title":"Acta Oncol"},{"key":"4147_CR26","doi-asserted-by":"publisher","first-page":"112967","DOI":"10.1016\/j.ejca.2023.112967","volume":"191","author":"N Lumlertgul","year":"2023","unstructured":"Lumlertgul N, Vassallo P, Tydeman F et al (2023) Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study. Eur J Cancer 191:112967. https:\/\/doi.org\/10.1016\/j.ejca.2023.112967","journal-title":"Eur J Cancer"},{"key":"4147_CR27","doi-asserted-by":"publisher","first-page":"13s","DOI":"10.1016\/s0002-9343(99)00113-8","volume":"106","author":"A Whelton","year":"1999","unstructured":"Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13s\u201324s. https:\/\/doi.org\/10.1016\/s0002-9343(99)00113-8","journal-title":"Am J Med"},{"key":"4147_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83099-y","volume":"11","author":"B Wu","year":"2021","unstructured":"Wu B, Li D, Xu T, Luo M, He Z, Li Y (2021) Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Sci Rep 11:3690. https:\/\/doi.org\/10.1038\/s41598-021-83099-y","journal-title":"Sci Rep"},{"key":"4147_CR29","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamainternmed.2018.4749","volume":"178","author":"S Brar","year":"2018","unstructured":"Brar S, Ye F, James MT, Hemmelgarn B, Klarenbach S, Pannu N (2018) Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. JAMA Intern Med 178:1681\u20131690. https:\/\/doi.org\/10.1001\/jamainternmed.2018.4749","journal-title":"JAMA Intern Med"},{"key":"4147_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/asn.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435\u2013446. https:\/\/doi.org\/10.1681\/asn.2019070676","journal-title":"J Am Soc Nephrol"},{"key":"4147_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid-Based Med"},{"key":"4147_CR32","unstructured":"GA Wells, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"},{"key":"4147_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1173952","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Wei W, Yang L et al (2023) Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol 14:1173952. https:\/\/doi.org\/10.3389\/fimmu.2023.1173952","journal-title":"Front Immunol"},{"key":"4147_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejim.2023.05.034","volume":"115","author":"W Xie","year":"2023","unstructured":"Xie W, Xiao S, Li X, Huang J, Li G, Zhang Z (2023) Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: systematic review and meta-analysis of real-world evidence. Eur J Intern Med 115:88\u201395. https:\/\/doi.org\/10.1016\/j.ejim.2023.05.034","journal-title":"Eur J Intern Med"},{"key":"4147_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad292","volume":"17","author":"JJ Chen","year":"2024","unstructured":"Chen JJ, Lee TH, Kuo G et al (2024) All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. Clin Kidney J 17:sfad292. https:\/\/doi.org\/10.1093\/ckj\/sfad292","journal-title":"Clin Kidney J"},{"key":"4147_CR36","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2215\/cjn.01390118","volume":"13","author":"G Fernandez-Juarez","year":"2018","unstructured":"Fernandez-Juarez G, Perez JV, Caravaca-Font\u00e1n F et al (2018) Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol 13:1851\u20131858. https:\/\/doi.org\/10.2215\/cjn.01390118","journal-title":"Clin J Am Soc Nephrol"},{"key":"4147_CR37","first-page":"63","volume":"5","author":"H Zhou","year":"2006","unstructured":"Zhou H, Hewitt SM, Yuen PS, Star RA (2006) Acute kidney injury biomarkers - needs, present status, and future promise. Nephrol Self-Assess Program 5:63\u201371","journal-title":"Nephrol Self-Assess Program"},{"key":"4147_CR38","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw382","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A (2017) Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 32:936\u2013942. https:\/\/doi.org\/10.1093\/ndt\/gfw382","journal-title":"Nephrol Dial Transplant"},{"key":"4147_CR39","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","volume":"5","author":"H Seethapathy","year":"2020","unstructured":"Seethapathy H, Zhao S, Strohbehn IA et al (2020) Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney Int Rep 5:1700\u20131705. https:\/\/doi.org\/10.1016\/j.ekir.2020.07.011","journal-title":"Kidney Int Rep"},{"key":"4147_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","author":"A Meraz-Mu\u00f1oz","year":"2020","unstructured":"Meraz-Mu\u00f1oz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C, Kim J, Wald R, Kitchlu A (2020) Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000467","journal-title":"J Immunother Cancer"},{"key":"4147_CR41","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","volume":"6","author":"B Isik","year":"2021","unstructured":"Isik B, Alexander MP, Manohar S et al (2021) Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events. Kidney Int Rep 6:1022\u20131031. https:\/\/doi.org\/10.1016\/j.ekir.2021.01.013","journal-title":"Kidney Int Rep"},{"key":"4147_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004421","author":"ML Baker","year":"2022","unstructured":"Baker ML, Yamamoto Y, Perazella MA et al (2022) Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004421","journal-title":"J Immunother Cancer"},{"key":"4147_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050679","author":"F Trevisani","year":"2022","unstructured":"Trevisani F, Di Marco F, Floris M et al (2022) Renal function outcomes in metastatic non-small-cell lung carcinoma patients treated with chemotherapy or immune checkpoint inhibitors: an unexpected scenario. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines10050679","journal-title":"Vaccines (Basel)"},{"key":"4147_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/23993693231161875","volume":"7","author":"P Garcia","year":"2023","unstructured":"Garcia P, Stedman MR, Merlo S, Kaghazchi A, Reddy S, Katsumoto TR, Anand S (2023) Kidney function while on immune checkpoint inhibitors: trends in incidence of acute kidney injury, and its causes and outcomes. J Onco-Nephrol 7:57\u201365. https:\/\/doi.org\/10.1177\/23993693231161875","journal-title":"J Onco-Nephrol"},{"key":"4147_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s11255-022-03395-y","volume":"55","author":"M Kanbay","year":"2023","unstructured":"Kanbay M, Yildiz AB, Siriopol D et al (2023) Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. Int Urol Nephrol 55:1025\u20131032. https:\/\/doi.org\/10.1007\/s11255-022-03395-y","journal-title":"Int Urol Nephrol"},{"key":"4147_CR46","doi-asserted-by":"publisher","first-page":"2326186","DOI":"10.1080\/0886022x.2024.2326186","volume":"46","author":"P Zhou","year":"2024","unstructured":"Zhou P, Liu B, Shen N, Fan X, Lu S, Kong Z, Gao Y, Lv Z, Wang R (2024) Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study. Ren Fail 46:2326186. https:\/\/doi.org\/10.1080\/0886022x.2024.2326186","journal-title":"Ren Fail"},{"key":"4147_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107325","volume":"184","author":"A Knox","year":"2023","unstructured":"Knox A, Cloney T, Janssen H, Solomon BJ, Alexander M, Ruderman I, John T (2023) Immune-related acute kidney injury in Australian non-small cell lung cancer patients: real-world results. Lung Cancer 184:107325. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107325","journal-title":"Lung Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04147-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:11:26Z","timestamp":1760962286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04147-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4147"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04147-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This meta-analysis utilized data from previously published studies, all of which had received the necessary ethical approvals and participant consent at the time of the original studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this meta-analysis is based on publicly available data, no further consent for publication is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study is a meta-analysis based on previously published data. No individual participant data is included, and therefore, consent to publish is not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"324"}}